Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of impaired antibody response after SARS-CoV-2 mRNA vaccination in hematopoietic cell transplant recipients: A Japanese multicenter observational study.
Mori Y, Uchida N, Harada T, Katayama Y, Wake A, Iwasaki H, Eto T, Morishige S, Fujisaki T, Ito Y, Kamimura T, Takahashi T, Imamura Y, Tanimoto K, Ishitsuka K, Sugita J, Kawano N, Tanimoto K, Yoshimoto G, Choi I, Hidaka T, Ogawa R, Takamatsu Y, Miyamoto T, Akashi K, Nagafuji K. Mori Y, et al. Among authors: harada t. Am J Hematol. 2023 Jan;98(1):102-111. doi: 10.1002/ajh.26769. Epub 2022 Oct 31. Am J Hematol. 2023. PMID: 36260658 Free PMC article.
Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data.
Mori Y, Jinnouchi F, Takenaka K, Aoki T, Kuriyama T, Kadowaki M, Odawara J, Ueno T, Kohno K, Harada T, Yoshimoto G, Takase K, Henzan H, Kato K, Ito Y, Kamimura T, Ohno Y, Ogawa R, Eto T, Nagafuji K, Akashi K, Miyamoto T. Mori Y, et al. Among authors: harada t. Bone Marrow Transplant. 2021 Apr;56(4):853-862. doi: 10.1038/s41409-020-01082-z. Epub 2020 Nov 2. Bone Marrow Transplant. 2021. PMID: 33139867
Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.
Harada T, Iwasaki H, Muta T, Urata S, Sakamoto A, Kohno K, Takase K, Miyamura T, Sawabe T, Asaoku H, Oryoji K, Fujisaki T, Mori Y, Yoshimoto G, Ayano M, Mitoma H, Miyamoto T, Niiro H, Yamamoto H, Oshiro Y, Miyoshi H, Ohshima K, Takeshita M, Akashi K, Kato K. Harada T, et al. Br J Haematol. 2021 Jul;194(1):101-110. doi: 10.1111/bjh.17456. Epub 2021 Apr 6. Br J Haematol. 2021. PMID: 33822354
TIM-3 marks measurable residual leukemic stem cells responsible for relapse after allogeneic stem cell transplantation.
Sakoda T, Kikushige Y, Irifune H, Kawano G, Harada T, Semba Y, Hayashi M, Shima T, Mori Y, Eto T, Kamimura T, Iwasaki H, Ogawa R, Yoshimoto G, Kato K, Maeda T, Miyamoto T, Akashi K. Sakoda T, et al. Among authors: harada t. Cancer Sci. 2024 Dec 26. doi: 10.1111/cas.16431. Online ahead of print. Cancer Sci. 2024. PMID: 39726280 Free article.
Immunology and targeted therapy in Castleman disease.
Tsunoda S, Harada T, Kikushige Y, Kishimoto T, Yoshizaki K. Tsunoda S, et al. Among authors: harada t. Expert Rev Clin Immunol. 2024 Sep;20(9):1101-1112. doi: 10.1080/1744666X.2024.2357689. Epub 2024 May 27. Expert Rev Clin Immunol. 2024. PMID: 38785062 Review.
WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies.
Oji Y, Inoue M, Takeda Y, Hosen N, Shintani Y, Kawakami M, Harada T, Murakami Y, Iwai M, Fukuda M, Nishida S, Nakata J, Nakae Y, Takashima S, Shirakata T, Nakajima H, Hasegawa K, Kida H, Kijima T, Morimoto S, Fujiki F, Tsuboi A, Morii E, Morita S, Sakamoto J, Kumanogoh A, Oka Y, Okumura M, Sugiyama H. Oji Y, et al. Among authors: harada t. Int J Cancer. 2018 Jun 1;142(11):2375-2382. doi: 10.1002/ijc.31253. Epub 2018 Jan 21. Int J Cancer. 2018. PMID: 29322496
4,222 results